P81 What is the ideal target preterm population that might benefit from the expensive palivizumab prophylaxis?
Sign Up to like & getrecommendations! Published in 2017 at "Thorax"
DOI: 10.1136/thoraxjnl-2017-210983.223
Abstract: Introduction Palivizumab is a monoclonal antibody that reduces the likelihood of serious respiratory tract infection by Respiratory Syncytial Virus (RSV) in infants with Chronic Lung Disease (CLD) defined as an ongoing oxygen requirement at 36… read more here.
Keywords: aap criteria; additional babies; palivizumab; jcvi criteria ... See more keywords